Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AZD6140 versus clopidogrel and placebo on onset and offset of antiplatelet effect in stable coronary artery disease
2006-006946-32Phase 2Completed
- Sponsor
- AstraZeneca
- Start
- Aug 2007
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of ticagrelor in coronary arteriosclerosis and arterial thrombosis (3 arms), sponsored by AstraZeneca. Primary endpoints: Inhibition of platelet aggregation at 2 hours after first dose and Slope of inhibition of platelet aggregation curves after last dose. Started Aug 2007; status: completed.
02
Drugs
ticagrelor
03
Conditions
coronary arteriosclerosisarterial thrombosis
Beyond the preview
Go deeper on 2006-006946-32.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-006946-32.